Skip to main content

Metformin-associated lactic acidosis: risk factors and prognostic factors

Introduction

Metformin, an oral hypoglycemic drug, belongs to the biguanide class and is now generally accepted as first-line treatment in type 2 diabetes mellitus, especially in overweight patients [1]. In some predisposing conditions, the use of metformin may result in metformin-associated lactic acidosis (MALA), a rare adverse event associated with a high mortality rate [2]. The aim of this study is to assess risk factors and prognostic factors in patients with MALA.

Methods

We conducted a retrospective study of patients with MALA admitted to the ICU of ASL 2 Chieti between 1 January 2008 and 30 September 2012. The eligibility criteria were: diagnosis of diabetes mellitus type 2, treatment with oral hypoglycemic drugs containing metformin, increased anion gap metabolic acidosis (pH <7.35, HCO3 <22 mmol/l, lactate >5 mmol/l). For each patient we evaluated: sex, age, home care, SAPS II score [3], blood tests.

Results

Ten patients were selected, five males and five females, with a mean age of 72.2. On admission, nine of 10 patients had a framework of general illness and acute renal failure; one patient appeared with a probable acute abdomen not subsequently confirmed on CT. Eight patients had a state of dehydration resulting from gastroenteritis, diarrhea, fever; two patients had taken NSAIDs in the days prior to hospitalization. No patient, in these conditions, has discontinued treatment with metformin. All patients showed a critical clinical framework with a SAPS II mean score of 77.5. Cardiovascular and respiratory support was required in all cases. The hemogas analysis showed that patients had a severe metabolic acidosis (mean pH = 6.96) with increased plasma lactate (mean lactate = 15.93 mmol/l). Prothrombin activity was normal in eight of 10 patients. The overall mortality was 70%.

Conclusion

Patient education on correct use of metformin is essential to prevent MALA, specially in those clinical conditions of increased risk (for example, acute renal failure), as recommended by the AIFA 2011 guidelines [4]. In our study, a higher plasma concentration of lactate represents the main negative prognostic factor, as pointed out by other studies [5]. The prothrombin activity, which is considered to be a decisive prognostic factor in the study of Peters and colleagues [6], was not impaired in patients with poor outcome.

References

  1. 1.

    UK Prospective Diabetes Study Group: Lancet. 1998, 352: 854-865.

    Article  Google Scholar 

  2. 2.

    Lalau JD: Drug Saf. 2010, 33: 727-740. 10.2165/11536790-000000000-00000

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Le Gall JR, et al.: JAMA. 1993, 270: 2957-2963. 10.1001/jama.1993.03510240069035

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Italian Medicines Agency 2011[http://www.agenziafarmaco.gov.it/it/content/raccomandazioni-sull%E2%80%99utilizzo-dei-medicinali-base-di-metformina-nella-gestione-del-diabete-m]

  5. 5.

    Dell'Aglio DM, et al.: Ann Emerg Med. 2009, 54: 818-823. 10.1016/j.annemergmed.2009.04.023

    Article  PubMed  Google Scholar 

  6. 6.

    Peters N, et al.: Crit Care. 2008, 12: R149. 10.1186/cc7137

    PubMed Central  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to V Di Falco.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Falco, V.D., Milano, A., Battilana, M. et al. Metformin-associated lactic acidosis: risk factors and prognostic factors. Crit Care 17, P453 (2013). https://doi.org/10.1186/cc12391

Download citation

Keywords

  • Diabetes Mellitus Type
  • Metformin
  • Acute Renal Failure
  • Metabolic Acidosis
  • Biguanide